Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary
R S
RS
Isis Pharmaceuticals, Inc., Carlsbad, CA 92008, USA. rgeary@isisph.com
Leeds
J M
JM
Henry
S P
SP
Monteith
D K
DK
Levin
A A
AA
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics* / Q000494:pharmacology*; D013045:Species Specificity; D013873:Thionucleotides / Q000493:pharmacokinetics* / Q000494:pharmacology*; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides